Antineoplastic-Anti-Lymphocyte Activation Gene-3 (LAG-3) MAb

Antineoplastic anti–lymphocyte activation gene-3 (LAG-3) monoclonal antibodies represent an immuno-oncology drug class comprising targeted checkpoint inhibitors that bind the inhibitory LAG-3 cell-surface receptor on exhausted T cells By blocking LAG-3 interactions with major histocompatibility complex class II molecules and other ligands, these antibodies relieve T-cell exhaustion and restore potent antitumor immune responses, most notably in synergy with programmed death receptor-1 (PD-1) inhi...

Antineoplastic anti–lymphocyte activation gene-3 (LAG-3) monoclonal antibodies represent an immuno-oncology drug class comprising targeted checkpoint inhibitors that bind the inhibitory LAG-3 cell-surface receptor on exhausted T cells

By blocking LAG-3 interactions with major histocompatibility complex class II molecules and other ligands, these antibodies relieve T-cell exhaustion and restore potent antitumor immune responses, most notably in synergy with programmed death receptor-1 (PD-1) inhibitors Clinically, the primary therapeutic application for this class is advanced cancer, specifically unresectable or metastatic melanoma, where agents such as relatlimab are administered in combination with anti–PD-1 therapy to impro...

By blocking LAG-3 interactions with major histocompatibility complex class II molecules and other ligands, these antibodies relieve T-cell exhaustion and restore potent antitumor immune responses, most notably in synergy with programmed death receptor-1 (PD-1) inhibitors

Clinically, the primary therapeutic application for this class is advanced cancer, specifically unresectable or metastatic melanoma, where agents such as relatlimab are administered in combination with anti–PD-1 therapy to improve progression-free survival